Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Posted by Geri Gentry on Jul 15th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $544.60, for a total transaction of $5,173,700.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,063,379.80. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $526.66 on Wednesday. The company has a market capitalization of $22.36 billion, a price-to-earnings ratio of 19.44, a PEG ratio of 1.79 and a beta of 0.58. The company has a 50-day simple moving average of $555.07 and a 200 day simple moving average of $529.82. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the prior year, the company earned $6.63 earnings per share. The firm’s revenue was down 1.6% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in shares of United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the fourth quarter valued at about $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on UTHR. HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

Get Our Latest Stock Analysis on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.